• Vitaspring Biomedical posted a net loss of USD 80,541 for the three months ended April 30, 2025, narrowing from USD 216,831 a year earlier.
• Operating loss improved to USD 69,147 as operating expenses fell 68.12% to USD 69,147.
• Revenue remained at no revenue as the company continued restructuring its commercial strategy and evaluating supplier and regulatory considerations.
• Income tax expense was USD 11,394, reflecting interest and penalties tied to fiscal 2022 historical tax obligations.
• Liquidity remained strained with a working capital deficiency of USD 4.11 million and no cash at quarter-end, as it sought additional capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vitaspring Biomedical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-001046), on June 15, 2026, and is solely responsible for the information contained therein.